Summary: Ferrari N.V.

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Highlights: Ferrari N.V.

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses: Ferrari N.V.

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.86 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings Chart: Ferrari N.V.

Source: Surperformance

ESG chart: Ferrari N.V.

Source: MSCI

Fundamentals (Composite) Global Valuation (Composite) Financial estimates revisions (Composite) Capi.($)
8.91TCr
4.6TCr
4.47TCr
2.85TCr
2.8TCr
2.69TCr
1.56TCr
890.85Cr
832.62Cr
254.42Cr
Average 2.99TCr
Weighted average by Cap.
See all sector ratings
Investor (Composite)
Trader (Composite)
ESG MSCI
BB

Financials

Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)

Valuation

P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield

Revisions

Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)

Business Predictability

Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence

ESG

Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes